PAS 003
Alternative Names: Alpha-5 - Pasithea Therapeutics; PAS-003Latest Information Update: 11 Aug 2025
At a glance
- Originator Alpha-5 Integrin
- Developer Pasithea Therapeutics
- Class Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Neurological disorders
Most Recent Events
- 11 Aug 2025 PAS 003 is available for licensing as of 11 Aug 2025. https://www.pasithea.com/pipeline/
- 01 Aug 2023 Pharmacodynamics data from a preclinical studies in Amyotrophic lateral sclerosis released by Pasithea Therapeutics
- 22 Jun 2022 Preclinical trials in Neurological disorders in USA (Parenteral)